Resistance Trends and Epidemiology of Acinetobacter Infections in Russia | CMAC

Resistance Trends and Epidemiology of Acinetobacter Infections in Russia

Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(2):96-105

​ Martinovich A.A.
Acinetobacter spp antimicrobial resistance carbapenemases
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(2):96-105

Abstract

In vitro activity of 13 antimicrobials (amikacin, cefepime, cefoperazone, cefoperazone/sulbactam, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, levofloxacin, meropenem, piperacillin, piperacillin/tazobactam) against 464 Acinetobacter spp. strains, isolated in 30 departments of 20 Russian cities in 2002–2004, and 18 antimicrobials (listed above, plus doripenem, colistin, polymyxin B, netilmycin and ticarcillin/clavulanic acid) against 333 Acinetobacter spp. strains, isolated in 29 departments of 20 Russian cities in 2006–2008 was investigated. MBL and acquired CHDL detection among 67 carbapenem-resistant Acinetobacter spp. was performed. An increase of antimicrobial resistance to almost all classes of antimicrobials was found among nosocomial Acinetobacter spp. The most active drugs in 2006–2008 were: colistin, polymyxin B, imipenem, doripenem, cefoperazone/sulbactam, meropenem and netilmicin with 100, 99.7, 97.3, 92.7, 89.7, 85.5 and 78.2% susceptible strains, respectively. Twenty nosocomial infections cases caused by OXA-23- and OXA-58-producing Acinetobacter strains in different regions were detected.

  • 1. Reacher, M.H., A. Shah, D.M. Livermore, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000;320:213-6.
  • 2. Krueger W.A., Unertl K.E. New treatment option for gram-positive infections in critically ill patients - overview over linezolid. Anasthesiol Intensivmed Notfallmed Schmerzther 2002; 37(4):199-204.
  • 3. Beltrбn M.A., Rodrнguez E., Sorvik D. et al. Clinical and epidemiological study of adult patients with positive blood cultures. Medicina (B Aires) 2002; 62(1):13-9.
  • 4. Cormican M.G., Jones R.N. Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci. Drugs 1996; 51 (Suppl 1):6-12.
  • 5. Jones R.N., Low D.E., Pfaller M.A. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 1999; 33(2):101-12.
  • 6. Rubinstein E., Bompart F. Activity of quinupristin/ dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. J Antimicrob Chemother 1997; 39 (Suppl A):139-43.
  • 7. Wade J.J. Enterococcus faecium in hospitals. Eur J Clin Microbiol Infect Dis 1997; 16(2):113-9.
  • 8. Jones R.N., Kirby J.T., Rhomberg P.R. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 2008; 61(2):203-13.
  • 9. Meatherall B.L., Gregson D., Ross T., Pitout J.D., Laupland K.B. Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med 2009; 122(9):866-73.
  • 10. Willemsen I., Mooij M., van der Wiel M., et al. Highly resistant microorganisms in a teaching hospital: the role of horizontal spread in a setting of endemicity. Infect Control Hosp Epidemiol 2008; 29(12):1110-7.
  • 11. Aly N.Y., Al-Mousa H.H., Al Asar el S.M. Nosocomial infections in a medical-surgical intensive care unit. Med Princ Pract 2008; 17(5):373-7.
  • 12. Hortal J., Muсoz P., Cuerpo G., Litvan H., Rosseel P.M., Bouza E; European Study Group on Nosocomial Infections; European Workgroup of Cardiothoracic Intensivists. Ventilator-associated pneumonia in patients undergoing major heart surgery: an incidence study in Europe. Crit Care 2009; 13(3):R80.
  • 13. Bartoszko-Tyczkowska A., Gaszyński W., Baranowska A., Tyczkowska-Sieroń E. Nosocomial infection control in intensive therapy. Anestesiol Intens Ter 2008; 40:232-6.
  • 14. Seifert H., Baginski R., Schulze A., Pulverer G. The distribution of Acinetobacter species in clinical culture materials. Zentralbl Bakteriol 1993; 279:544–52.
  • 15. Van Looveren M., Goossens H. and the ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10:684-704.
  • 16. Glew R.H., Moellering R.C. Jr., Kunz L.J. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore). 1977; 56(2):79-97.
  • 17. Gaughan M., White P.M., Noble W.C. Skin as a source of Acinetobacter/Moraxella species. J Clin Pathol. 1979; 32(11):1193.
  • 18. Crues J.V., Murray B.E., Moellering R.C. In vitro activity of three tetracycline antibiotics against Acinetobacter calcoaceticus subsp. anitratus. Antimicrob Agents Chemother 1979; 16(5):690-2.
  • 19. Emori T.G., Gaynes R.P. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6:428-42.
  • 20. Hanberger H., Garcia Rodriguez J.A., Gobernado M., et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999; 281:67-71.
  • 21. Murray B.E., Moellering R.C. Aminoglycoside-modifying enzymes among clinical isolates of Acinetobacter calcoaceticus subsp. anitratus (Herellea vaginicola): explanation for high-level aminoglycoside resistance. Antimicrob Agents Chemother 1979; 15(2):190-9.
  • 22. Seifert H., Baginski R., Schulze A., Pulverer G. Anti­microbial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 1993; 37:750–3.
  • 23. Traub W.H., Spohr M. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6). Antimicrob Agents Chemother 1989; 33:1617-9.
  • 24. Vila J., Marcos A., Marco F., et al. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993; 37:138-41.
  • 25. Shi Z.Y., Liu P.Y., Lau Y., Lin Y., Hu B.S., Shir J.-M. Antimicrobial susceptibility of clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis 1996; 24:81-5.
  • 26. Giamarellou H., Antoniadou A., Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents 2008; 32(2):106-19.
  • 27. Paton R.H., Miles R.S., Hood J., Amyes S.G.B. ARI-1: βlactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents 1993; 2:81-8.
  • 28. Montefour K., Frieden J., Hurst S., et al. Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse 2008; 28(1):15-25.
  • 29. Federico Perez, Andrea M. Hujer, Kristine M. Hujer et al. Global Challenge of Multidrug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51(10):3471-84
  • 30. Wisplinghoff H., Edmond M.B., Pfaller M.A., Jones R.N., Wenzel R.P., Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000; 31:690- 7
  • 31. Fagon J.Y., Chastre J., Hance A.J., Montravers P., Novara A., and Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94:281-8
  • 32. Chastre J. Infections due to Acinetobacter baumannii in the ICU. Semin Respir Crit Care Med. 2003; 24(1):69- 78.
  • 33. Lizaso D., Aguilera C.K., Correa M., et al. Nosoco­mial bloodstream infections caused by gram-negative bacilli: epidemiology and risk factors for mortality. Rev Chilena Infectol 2008; 25(5):368-73.
  • 34. Pournaras S., Iosifidis E., Roilides E. Advances in antibacterial therapy against emerging bacterial pathogens. Semin Hematol. 2009; 46(3):198-211.
  • 35. Naas T.M., Levy C., Hirschauer H., Marchandin and P. Nordmann. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol 2005; 43:4826-9.
  • 36. Dizbay M., Altuncekic A., Sezer B.E., Ozdemir K., Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008; 32(1):29-32.
  • 37. Park Y.K., Choi J.Y., Jung S.I., et al. Two distinct clones of carbapenem-resistant Acinetobacter baumannii isolates from Korean hospitals. Diagn Microbiol Infect Dis 2009; 64(4):389-95.
  • 38. McCracken M., DeCorby M., Fuller J., et al. Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: results from CANWARD 2007. J Antimicrob Chemother 2009; 64(3):552-5.
  • 39. Jamal W., Salama M., Dehrab N., Al Hashem G., Shahin M., Rotimi V.O. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Hosp Infect 2009; 72(3):234-42.
  • 40. Fernandez-Cuenca F., L. Martinez-Martinez M.C. Conejo J.A. Ayala, E.J. Perea, and A. Pascual.. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob. Chemother 2003; 51:565-74.
  • 41. Clark R.B. Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33–36 kDa outer membrane protein. J Antimicrob. Chemother 1996; 38:245-51.
  • 42. Limansky, A.S., Mussi M.A., and Viale A.M.. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J Clin Microbiol 2002; 40:4776-8.
  • 43. Huang L., Sun L., Xu G., Xia T. Differential susceptibility to carbapenems due to the AdeABC efflux pump among nosocomial outbreak isolates of Acinetobacter baumannii in a Chinese hospital. Diagn Microbiol Infect Dis 2008; 62(3):326-32.
  • 44. Mostachio A.K., van der Heidjen I.M., Rossi F., Levin A.S., Costa S.F. Multiplex PCR for rapid detection of genes encoding Oxa and metallo-beta-lactamases in carbapenem resistant Acinetobacter spp. J Med Microbiol 2009; 58(Pt 11):1522-4.
  • 45. Uma Karthika R., Srinivasa R.R., Sahoo S., et al. Phenotypic and genotypic assays for detecting the prevalence of metallo-beta-lactamases in clinical isolates of Acinetobacter baumannii from a South Indian tertiary care hospital. J Med Microbiol 2009; 58:430-5.
  • 46. Irfan S., Zafar A., Guhar D., Ahsan T., Hasan R. Metallobeta-lactamase-producing clinical isolates of Acinetobacter species and Pseudomonas aeruginosa from intensive care unit patients of a tertiary care hospital. Indian J Med Microbiol 2008; 26(3):243-5.
  • 47. Ikonomidis A., Ntokou E., Maniatis A.N., Tsakris A., Pournaras S. Hidden VIM-1 metallo-beta-lactamase phenotypes among Acinetobacter baumannii clinical isolates. J Clin Microbiol 2008; 46(1):346-9.
  • 48. Wroblewska M.M., Towner K.J., Marchel H., Luczak M. Emergence and spread of carbapenem-resistant strains of Acinetobacter baumannii in a tertiary-care hospital in Poland. Clin Microbiol Infect 2007; 13(5):490-6.
  • 49. Ait El Kadi M, Aghrouch M, Seffar M, et al. Prevalence of Acinetobacter baumannii and Pseudomonas aeruginosa isolates resistant to imipenem by production of metallobeta-lactamase. Med Mal Infect 2006; 36(7):386-9.
  • 50. Tognim M.C., Gales A.C., Penteado A.P., Silbert S., Sader H.S. Dissemination of IMP-1 metallo- beta -lactamase-producing Acinetobacter species in a Brazilian teaching hospital. Infect Control Hosp Epidemiol 2006; 27(7):742-7.
  • 51. Gallego L., Canduela M.J., Sevillano E., Pujana I., Calvo F., Umaran A., Martнn G. Carbapenemase detection in Acinetobacter baumannii clones resistant to imipenem. Enferm Infecc Microbiol Clin 2004; 22(5):262-6.
  • 52. Adams-Haduch J.M., Paterson D.L., Sidjabat H.E., et al. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother 2008; 52(11):3837-43.
  • 53. Carvalho K.R., Carvalho-Assef A.P., Peirano G., Santos L.C., Pereira M.J., Asensi M.D. Dissemination of multidrug-resistant Acinetobacter baumannii genotypes carrying bla(OXA-23) collected from hospitals in Rio de Janeiro, Brazil. Int J Antimicrob Agents 2009; 34:25-8.
  • 54. Castanheira M., Mendes R.E., Rhomberg P.R., Jones R.N. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Resist 2008; 14(3):211-6.
  • 55. Coelho J., Woodford N., Afzal-Shah M., Livermore D. Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents. Antimicrob Agents Chemother 2006; 50:756-8.
  • 56. Da Silva G.J., Quinteira S., Bйrtolo E., et al. Long-term dissemination of an OXA-40 carbapenemase-producing Acinetobacter baumannii clone in the Iberian Peninsula. J Antimicrob Chemother 2004; 54(1):255-8.
  • 57. Turton J.F., Ward M.E., Woodford N., Kaufmann M.E., Pike R., Livermore D.M., Pitt T.L. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006; 258(1):72-7.
  • 58. Turton J.F., Woodford N., Glover J., Yarde S., Kaufmann M.E., Pitt T.L. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol 2006; 44(8):2974-6.
  • 59. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 19th Informational Supplement; M100-S19;29(3).
  • 60. Шевченко О.В., Эйдельштейн М.В., Степанова М.Н. Металло-бета-лактамазы: значение и методы выявления у грамотрицательных неферментирующих бактерий. Clinical Microbiology and Antimicrobial Chemotherapy.2007; 9(3):211-8.
  • 61. Научный отчёт по исследованию госпитального потребления системных АМП в РФ. (2006 г.) НИИАХ ГОУ ВПО СГМА Росздрава.
  • 62. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфекционной химиотерапии. 3-е издание. Смоленск, МАКМАХ, 2007.
  • 63. Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., Bonomo R.A. Global challenge of multidrugresistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(10):3471-84.
  • 64. Turner P.J. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008; 60(2):185-92.
  • 65. Unal S., Garcia-Rodriguez J.A. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2005; 53(4):265- 71.
  • 66. Héritier C., Poirel L., Aubert D., Nordmann P. Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of Acinetobacter baumannii. Antimicrob Agents Chemother 2003; 47(1):268-73.
  • 67. Poirel L., Marquй S., Hйritier C., Segonds C., Chabanon G., Nordmann P. OXA-58, a novel class D {beta}- lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49(1):202-8.
  • 68. Ruiz M., Marti S., Fernandez-Cuenca F., Pascual A., Vila J. High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain. Clin Microbiol Infect 2007; 13(12):1192-8.
  • 69. Quinteira S., Grosso F., Ramos H., Peixe L. Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. Antimicrob Agents Chemother 2007; 51(9):3465-6.
  • 70. Tan X.S., Liu Y., Han X.P. Preliminary investigation of the molecular mechanisms of imipenem-resistance in clinical isolates of Acinetobacter baumannii in Xi’an. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29(7):1393-6.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared